MCID: TNP001
MIFTS: 41

Tinea Pedis

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Tinea Pedis

MalaCards integrated aliases for Tinea Pedis:

Name: Tinea Pedis 12 45 15 17 74
Athlete's Foot 12 77 44 64
Dermatophytosis of Foot 12
Ringworm of Foot 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12403
ICD9CM 36 110.4
MeSH 45 D014008
SNOMED-CT 69 6020002
ICD10 34 B35.3
UMLS 74 C0040259

Summaries for Tinea Pedis

MedlinePlus : 44 Athlete's foot is a common infection caused by a fungus. It most often affects the space between the toes. Symptoms include itching, burning, and cracked, scaly skin between your toes. You can get athlete's foot from damp surfaces, such as showers, swimming pools, and locker room floors. To prevent it Keep your feet clean, dry, and cool Wear clean socks Don't walk barefoot in public areas Wear flip-flops in locker room showers Keep your toenails clean and clipped short Treatments include over-the-counter antifungal creams for most cases and prescription medicines for more serious infections. These usually clear up the infection, but it can come back. Centers for Disease Control and Prevention

MalaCards based summary : Tinea Pedis, also known as athlete's foot, is related to tinea corporis and tinea manuum, and has symptoms including scaling, fissures and maceration. An important gene associated with Tinea Pedis is SQLE (Squalene Epoxidase), and among its related pathways/superpathways is Metabolism. The drugs Miconazole and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and skin of foot, and related phenotype is Decreased HIV-LTR-beta-galactosidase protein expression.

Disease Ontology : 12 A dermatophytosis that results in fungal infection located in skin of foot, especially between the toes, has material basis in Trichophyton or has material basis in Epidermophyton and has symptom fissures, has symptom scaling, has symptom maceration, and eroded areas between the toes and on the plantar surface of the foot.

PubMed Health : 64 About athlete's foot: Many people will have athlete's foot at some time throughout their life. It is usually the gaps between the toes that are affected. Athlete's foot can normally be treated effectively with creams available from the pharmacy. To prevent athlete's foot from developing at all, it is important to keep your feet dry.

Wikipedia : 77 Athlete''s foot, known medically as tinea pedis, is a common skin infection of the feet caused by... more...

Related Diseases for Tinea Pedis

Diseases related to Tinea Pedis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
# Related Disease Score Top Affiliating Genes
1 tinea corporis 30.3 ARSI SQLE
2 tinea manuum 11.7
3 dermatophytosis 10.7
4 tinea cruris 10.7
5 tinea unguium 10.6
6 erythrasma 10.4
7 dermatitis 10.4
8 tinea capitis 10.3
9 dermatitis, atopic 10.2
10 diabetes mellitus 10.2
11 sarcoma 10.2
12 erysipelas 10.2
13 candidiasis 10.2
14 mycosis fungoides 10.1
15 basal cell carcinoma 1 10.1
16 diabetic foot ulcers 10.1
17 skin conditions 10.1
18 skin disease 10.1
19 superficial mycosis 10.1
20 cutaneous candidiasis 10.1
21 oral candidiasis 10.1
22 melanoma 10.1
23 basal cell carcinoma 10.1
24 palmoplantar keratosis 10.1
25 cellulitis 10.1
26 nodular basal cell carcinoma 10.1
27 acral lentiginous melanoma 10.1
28 psoriasis 10.1
29 pityriasis versicolor 10.1

Comorbidity relations with Tinea Pedis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Hypertension, Essential
Peripheral Vascular Disease Tinea Manuum
Venous Insufficiency

Graphical network of the top 20 diseases related to Tinea Pedis:



Diseases related to Tinea Pedis

Symptoms & Phenotypes for Tinea Pedis

Symptoms:

12
  • scaling
  • fissures
  • maceration

UMLS symptoms related to Tinea Pedis:


fever, pruritus, exanthema

GenomeRNAi Phenotypes related to Tinea Pedis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased HIV-LTR-beta-galactosidase protein expression GR00224-A-1 8.62 BCLAF1 TECR

Drugs & Therapeutics for Tinea Pedis

PubMedHealth treatment related to Tinea Pedis: 64

Athlete's foot can usually be treated effectively with creams, gels or sprays that are available from pharmacies without a prescription. These products contain an ingredient that stops the growth of the fungus or kills it. But the treatment does require some patience.Home remedies such as tea tree oil or foot baths containing herbal products are sometimes recommended. But there is no scientific that they are effective against athlete's foot.Tablets are also an option if athlete's foot cannot be successfully treated topically. But that is only rarely necessary and must be given careful consideration because the risk of side effects is higher.

Drugs for Tinea Pedis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Luliconazole Approved Phase 4,Phase 2 187164-19-8
4
Naftifine Approved Phase 4,Phase 3,Phase 1 65472-88-0 47641 73342
5 Anti-Ulcer Agents Phase 4
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antacids Phase 4
8 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Gastrointestinal Agents Phase 4
10 Proton Pump Inhibitors Phase 4
11
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
12
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
13
Clotrimazole Approved, Vet_approved Phase 3,Phase 1 23593-75-1 2812
14
Ketoconazole Approved, Investigational Phase 3,Phase 2,Phase 1 65277-42-1 47576
15
Econazole Approved Phase 3,Phase 2 27220-47-9 3198
16
Terbinafine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 91161-71-6 5402 1549008
17
Ciclopirox Approved, Investigational Phase 3,Not Applicable 29342-05-0 2749
18 Pharmaceutical Solutions Phase 3,Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
21 Cytochrome P-450 CYP3A Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
22 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
23 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
24 Steroid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
25
Nitric Oxide Approved Phase 2 10102-43-9 145068
26
Racepinephrine Approved Phase 2 329-65-7 838
27
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
28
Bifonazole Approved, Investigational Phase 2 60628-96-8 2378
29 Endothelium-Dependent Relaxing Factors Phase 2
30 Bronchodilator Agents Phase 2
31 Respiratory System Agents Phase 2
32 Protective Agents Phase 2
33 Peripheral Nervous System Agents Phase 2
34 Vasodilator Agents Phase 2,Phase 1
35 Antioxidants Phase 2
36 Neurotransmitter Agents Phase 2
37 Free Radical Scavengers Phase 2
38 Autonomic Agents Phase 2
39 Anti-Asthmatic Agents Phase 2
40 Epinephryl borate Phase 2
41 Anti-Inflammatory Agents Phase 2
42 Antibodies Phase 2
43 Immunologic Factors Phase 2
44 Antibodies, Monoclonal Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46 Immunoglobulins Phase 2
47
Oxiconazole Approved Phase 1 64211-46-7, 64211-45-6 5361463
48
Butenafine Approved Phase 1 101828-21-1 2484
49
Glucosamine Approved, Investigational Phase 1 3416-24-8 439213
50
Bradykinin Investigational Phase 1 58-82-2 439201

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4 Omeprazole 40mg
2 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
3 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
4 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
5 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3 Clotrimazole
6 Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis Completed NCT03824912 Phase 3 Ketoconazole Cream 2%;Ketoconazole Cream 2% (G&W Laboratories Inc.);Placebo
7 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
8 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
9 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
10 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
11 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
12 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
13 Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
14 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
15 Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Completed NCT01349998 Phase 3 Product 33525
16 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
17 Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
18 BE Study of Naftifine HCL Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
19 Non-inferiority Trial of Dapaconazole Versus Ketoconazole Recruiting NCT03320486 Phase 3 Dapaconazole;Ketoconazole
20 An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot Terminated NCT01110330 Phase 3 Placebo cream;Ketoconazole 2% cream (formulation F012) (Nizoral);Ketoconazole 2% cream (formulation F126)
21 Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis Withdrawn NCT02606383 Phase 3 Dapaconazole;Ketoconazole
22 Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot Unknown status NCT02871011 Phase 2 Nitric Oxide;Water
23 Three-Arm Trial of Novel Treatment for Tinea Pedis Completed NCT03135912 Phase 2 Experimental Drug SESC 01;Placebo;Terbinafine Hydrochloride
24 Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis Completed NCT02842021 Phase 2 S2G6T-1;S2G6T-2;S2G6T-3;S2G6T-4
25 SB208 for the Treatment of Tinea Pedis Completed NCT02860052 Phase 2 SB208 2%;SB208 4%;SB208 16%;Vehicle Gel
26 Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis Completed NCT01096472 Phase 2 LAS41003;LAS189961;LAS189962
27 Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis Completed NCT02824926 Phase 2 Dapaconazole;Ketoconazole
28 A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis Completed NCT00893880 Phase 2 1% gaseous Nitric Oxide blended in Oxygen
29 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis Completed NCT01891305 Phase 2 VT-1161;placebo
30 Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot) Completed NCT00869336 Phase 2 Luliconazole Cream 1% - 2 wks;Placebo Comparator -2 wks;Luliconazole Cream 1% - 4 wks;Placebo Comparator - 4 wks
31 Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years Completed NCT01696799 Phase 2 Econazole Nitrate;placebo
32 A Study of Econazole Foam 1% in Athlete's Foot Completed NCT00768599 Phase 2 Econazole Nitrate Cream 1%;Econazole Nitrate Foam 1%;Vehicle Foam
33 Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot) Completed NCT00771342 Phase 2 Nitric Oxide;Nitrogen
34 Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo Completed NCT01013909 Phase 2 Bifonazole spray once daily;Bifonazole spray twice daily;Placebo;Placebo;Lamisil Once
35 Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai Completed NCT02238912 Phase 2 kandhaga rasayanam
36 A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis Recruiting NCT03897257 Phase 2 UHE-103A1 cream;UHE-103A2 cream;UHE-103B cream;UHE-103A1B cream;UHE-103A2B cream
37 Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer Terminated NCT01137071 Phase 2
38 A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis Completed NCT01519752 Phase 1 Oxiconazole Nitrate Cream 1%;Oxiconazole Nitrate Cream 1% (Oxistat®);Placebo
39 Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis Completed NCT02132260 Phase 1 Naftifine Hydrochloride Cream 2%;Naftin® (Naftifine Hydrochloride) Cream 2%;Placebo Topical Cream
40 Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis Completed NCT00835510 Phase 1 Butenafine cream 1% manufactured by Taro;Lotrimin Ultra (butenafine) 1%;Butenafine Vehicle manufactured by Taro
41 Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis Completed NCT01580891 Phase 1 Naftifine HCl Cream 1%;Naftin® (Naftifine HCl) Cream 1%;Placebo topical cream
42 Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis Completed NCT01580878 Phase 1 Butenafine Hydrochloride Cream, 1%;Lotrimin Ultra®;Butenafine Vehicle
43 Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis Completed NCT01524432 Phase 1 Anti-fungal agent (Clotrimazole) loaded microcapsules;Placebo
44 Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Completed NCT02335255 Phase 1 Naftifine Hydrochloride Gel 2%;Naftin® Gel 2%;Placebo Topical Gel
45 A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP) Completed NCT00509275 Phase 1 W0027;Placebo
46 Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis Completed NCT00691184 Phase 1 Placebo;Terbinafine Hydrochloride;Terbinafine Hydrochloride;Terbinafine
47 Cumulative Irritation Test Completed NCT00781664 Phase 1 AN2718;AN2718;AN2718;AN2718;AN2718;AN2718
48 Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel Completed NCT03823040 Phase 1 Oxiconazole Nitrate Cream 1%;Oxiconazole nitrate SLNs loaded gel.
49 A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers Completed NCT00501397 Phase 1 ketoconazole;GSK189075
50 Effects of Miconazole on Blood Flow Completed NCT00004575 Phase 1 Miconazole, L-NMMA, Bradykinin

Search NIH Clinical Center for Tinea Pedis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: tinea pedis

Genetic Tests for Tinea Pedis

Anatomical Context for Tinea Pedis

MalaCards organs/tissues related to Tinea Pedis:

42
Skin, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Pedis:

20
Skin Of Foot

Publications for Tinea Pedis

Articles related to Tinea Pedis:

(show top 50) (show all 496)
# Title Authors Year
1
Consumer Preferences of Antifungal Products for Treatment and Prevention of Tinea Pedis. ( 30661432 )
2019
2
Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. ( 30768808 )
2019
3
Blad-containing oligomer: a novel fungicide used in crop protection as an alternative treatment for tinea pedis and tinea versicolor. ( 29388537 )
2018
4
Response to: Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". ( 29951161 )
2018
5
Dapaconazole versus ketoconazole in the treatment of interdigital tinea pedis. ( 29191265 )
2018
6
Treatment of Signs and Symptoms (Pruritus) of Interdigital Tinea Pedis With Econazole Nitrate Foam, 1. ( 29462232 )
2018
7
Efficacy of combination of ozonated water with oil for treatment of tinea pedis. ( 29559597 )
2018
8
Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". ( 29849837 )
2018
9
Skin microbiome changes in patients with interdigital tinea pedis. ( 29704463 )
2018
10
Tinea pedis acquired in mosques? ( 29600810 )
2018
11
A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis. ( 30124729 )
2018
12
Cholesterol, cancer, and rebooting a treatment for athlete's foot. ( 29669852 )
2018
13
Analysis on curative effects and safety of 2% liranaftate ointment in treating tinea pedis and tinea corporis & cruris. ( 28671089 )
2017
14
Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia. ( 28852411 )
2017
15
Brief report: Tinea pedis, active component, U.S. Armed Forces, 2000-2016. ( 28570090 )
2017
16
Successive potassium hydroxide testing for improved diagnosis of tinea pedis. ( 28961287 )
2017
17
Examining the accuracy of visual diagnosis of tinea pedis and tinea unguium in aged care facilities. ( 28379097 )
2017
18
Vinegar Sock Soak for Tinea Pedis or Onychomycosis. ( 28947288 )
2017
19
Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with typeA 2 diabetes in Turkey. ( 27667305 )
2017
20
Treatment of Tinea Pedis in Elderly Patients Using External Preparations. ( 28566665 )
2017
21
The Association between Tinea Pedis and Feet-Washing Behavior in Patients with Diabetes: A Cross-sectional Study. ( 29049259 )
2017
22
Tinea, Pedis ( 29262247 )
2017
23
Increased Risk of Tinea Pedis and Onychomycosis Among Swimming Pool Employees in Netanya Area, Israel. ( 27435974 )
2016
24
Introduction to Advances in Tinea Pedis Management. ( 26885797 )
2016
25
Evaluation of local trace element status and 8-Iso-prostaglandin F2I+ concentrations in patients with Tinea pedis. ( 26740800 )
2016
26
Tinea pedis due to Cylindrocarpon lichenicola beginning onycholysis. ( 26958461 )
2016
27
Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. ( 27057486 )
2016
28
Gyrate erythema in the setting of tinea pedis. ( 28329539 )
2016
29
Econazole Nitrate Foam 1% Improves the Itch of Tinea Pedis. ( 27602974 )
2016
30
The Role of Naftifine HCl 2% Gel and Cream in Treating Moccasin Tinea Pedis. ( 26885800 )
2016
31
Enhancement of the topical tolnaftate delivery for the treatment of tinea pedis via provesicular gel systems. ( 27666873 )
2016
32
Mycosis fungoides mimicking tinea pedis. ( 27799613 )
2016
33
Fungal interdigital tinea pedis in Dakar (Senegal). ( 27184614 )
2016
34
Tinea pedis and onychomycosis frequency in diabetes mellitus patients and diabetic foot ulcers. A cross sectional - observational study. ( 27648034 )
2016
35
Luliconazole Retention in Stratum Corneum and Prevention of Fungal Infection in a Guinea Pig Tinea Pedis Model. ( 26741388 )
2016
36
Development and evaluation of ultra-small nanostructured lipid carriers: novel topical delivery system for athlete's foot. ( 26542152 )
2016
37
Association between Washing Residue on the Feet and Tinea Pedis in Diabetic Patients. ( 25793125 )
2015
38
Once-daily luliconazole cream 1% for the treatment of interdigital tinea pedis. ( 26559086 )
2015
39
An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftifine HCl Gel 2% in Pediatric Subjects With Tinea Pedis. ( 26151784 )
2015
40
Management of onychomycosis and co-existing tinea pedis. ( 25942668 )
2015
41
Efinaconazole Topical Solution, 10% Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis. ( 26429609 )
2015
42
Identifying Signs of Tinea Pedis: A Key to Understanding Clinical Variables. ( 26461834 )
2015
43
Efinaconazole Topical Solution, 10%: Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis. ( 25867759 )
2015
44
Diagnosis of tinea pedis by the Dermatophyte Test Strip. ( 26114807 )
2015
45
Tinea pedis presenting as asymmetric purpuric papules on the sole of the foot: a case report. ( 25873874 )
2015
46
Adherence to oral and topical medication in 445 patients with tinea pedis as assessed by the Morisky Medication Adherence Scale-8. ( 26574949 )
2015
47
D-optimal experimental approach for designing topical microemulsion of itraconazole: Characterization and evaluation of antifungal efficacy against a standardized Tinea pedis infection model in Wistar rats. ( 25445834 )
2015
48
Naftifine Hydrochloride Gel 2%: An Effective Topical Treatment for Moccasin-Type Tinea Pedis. ( 26461826 )
2015
49
Interaction between Pseudomonas aeruginosa and dermatophyte fungi: Repercussions on the clinical course and microbiological diagnosis of tinea pedis. ( 26427732 )
2015
50
Not only athlete's foot survives in feet. ( 25342847 )
2015

Variations for Tinea Pedis

Expression for Tinea Pedis

Search GEO for disease gene expression data for Tinea Pedis.

Pathways for Tinea Pedis

Pathways related to Tinea Pedis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 ARSI GSTM4 SQLE TECR TRIT1

GO Terms for Tinea Pedis

Sources for Tinea Pedis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....